News from mgb biopharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

10 Oct, 2019, 10:30 BST MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance,...


30 Aug, 2019, 09:00 BST MGB Biopharma Announces Completion of Funding Round

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance,...


24 Jan, 2019, 09:00 GMT MGB Biopharma - FDA and Health Canada Clear IND/CTA Applications for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)

Phase IIa trial to evaluate MGB-BP-3 in patients with CDAD on track to start in Q1 2019 MGB Biopharma, a biopharmaceutical company developing a novel ...


06 Apr, 2017, 09:00 BST MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance,...


12 Sep, 2016, 09:00 BST MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridium Difficile-associated Diarrhoea (CDAD) for MGB-BP-3

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance,...


14 Jun, 2016, 09:00 BST MGB Biopharma to Present Poster at Upcoming ASM Microbe Meeting in Boston on 20 June 2016

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic...


19 May, 2016, 11:11 BST MGB Biopharma Welcomes Jim O'Neill's Final Recommendations for the World to Defeat Superbugs

MGB Biopharma, a Biopharmaceutical Company Developing a Truly Novel Class of Anti-infectives, Welcomes the Final Instalment of Lord Jim O'Neill's...


09 May, 2016, 08:00 BST MGB Biopharma's Pre-IND Meeting With FDA Provides Clear Guidelines on Further Development of Oral MGB-BP-3, a Truly Novel Antibiotic Targeting Clostridium Difficile Infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic...


15 Feb, 2016, 09:00 GMT MGB Biopharma and University of Strathclyde Sign New Agreement to Develop Novel MGB Anti-Infectives to Tackle a Key Mechanism of AMR

New compounds designed to overcome efflux pump mediated bacterial resistance MGB Biopharma, a biopharmaceutical company developing a truly novel...


21 Jul, 2015, 09:00 BST MGB Biopharma Commences Phase I Clinical Trial With Oral Formulation of MGB-BP-3 for the Treatment of Multi-Resistant Clostridium Difficile Infections

- MGB Biopharma is at the forefront of efforts to tackle the global rise in antibiotic resistant infections MGB Biopharma, a biopharmaceutical...


02 Jun, 2015, 09:00 BST MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections

MGB Biopharma at the forefront of addressing the global antibiotic resistance problem MGB Biopharma, a biopharmaceutical company developing a truly...


12 Jan, 2015, 09:00 GMT MGB Biopharma Continues to Progress its Truly Novel Anti-infectives Platform to Tackle Antibiotic Resistance in 2014

Highlights In September 2014, MGB Biopharma secured £4M ($6.4M) from leading Scottish investors and Innovate UK for further clinical development of...


17 Sep, 2014, 09:00 BST MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development

First antibacterial with a new mode of action from a truly novel class of anti-infective in over a decade MGB Biopharma, a biopharmaceutical company...


09 Jun, 2014, 12:30 BST MGB Biopharma Receives £1.3m Grant Award from the UK's Technology Strategy Board's Biomedical Catalyst

Grant to help fund Phase I trial with lead candidate oral MGB-BP-3 for Clostridium difficile MGB Biopharma, a biopharmaceutical company developing...


02 Jun, 2014, 09:00 BST MGB Biopharma Expands Scientific Advisory Board (SAB) with Medical Microbiologist Dr Stephanie Dancer

MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that Dr Stephanie Dancer, an internationally...


18 Nov, 2013, 09:00 GMT MGB Biopharma Adds its Support to European Antibiotic Awareness Day

MGB Biopharma, one of Europe's leading biopharmaceutical companies developing truly novel anti-infectives, announces its support for the European...


04 Nov, 2013, 09:11 GMT MGB Biopharma to Present at Bio-Europe 2013

MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that CEO Dr Miroslav Ravic will present at...